Stock listing
BBIO Stock Price, News, Filings & Events — Bridgebio Pharma, Inc.
Selected listing: BBIO · BX · CHF · CH
This page tracks Bridgebio Pharma, Inc.'s BBIO:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BBIO:BX. BBIO:BX is the stock-level entry point for investors researching Bridgebio Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Bridgebio Pharma, Inc. is a public company traded under the ticker BBIO in the American market. With a market capitalization of approximately $16.47 billion, the company focuses on developing innovative therapies for genetic diseases and cancers. Bridgebio aims to address significant unmet medical needs through its research and development efforts.
- Ticker
- BBIO:BX
- Asset type
- Stock
- Market cap
- $14.97B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- BX
- Currency
- CHF
Bridgebio Pharma, Inc. BBIO:BX stock context
This page tracks Bridgebio Pharma, Inc.'s BBIO:BX listing on BX in CHF for CH, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following BBIO:BX. BBIO:BX is the stock-level entry point for investors researching Bridgebio Pharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Bridgebio Pharma, Inc. is a public company traded under the ticker BBIO in the American market. With a market capitalization of approximately $16.47 billion, the company focuses on developing innovative therapies for genetic diseases and cancers. Bridgebio aims to address significant unmet medical needs through its research and development efforts.
Latest news from Bridgebio Pharma, Inc.
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease ...
August 26, 2026
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026
Bridgebio Pharma, Inc. earnings calls
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call
August 10, 2026 · Replay with transcript and chapters
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call
February 24, 2026 · Replay with transcript and chapters
BridgeBio Pharma, Inc. (BBIO) Q3 2025 Earnings Call
October 29, 2025 · Replay with transcript and chapters
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call
August 5, 2025 · Replay with transcript and chapters
BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call
April 29, 2025 · Replay with transcript and chapters
Research Bridgebio Pharma, Inc.
Bridgebio Pharma, Inc. investor report
Review AI stock analysis and investor report context for BBIO:BX.
Bridgebio Pharma, Inc. company profile
View the public company page for Bridgebio Pharma, Inc. on 6ix.
Bridgebio Pharma, Inc. news
Read company news and market updates connected to Bridgebio Pharma, Inc..
Bridgebio Pharma, Inc. investor events
Find investor webinars, events, and replay context for Bridgebio Pharma, Inc..
Alternate listings
BBIO:NASDAQ
US · USD
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:GETTEX
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
A2PLX7:LSX
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:TRADEGATE
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
A2PLX7:LS
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
1BBIO:MIL
IT · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
BBIO:BOATS
US · USD
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:FWB
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:DUS
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:HAM
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:MUN
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.
2CL:SWB
DE · EUR
Alternate listing for Bridgebio Pharma, Inc.; the primary context on this page is BBIO:BX.